Penetration of aztreonam into cerebrospinal fluid of patients with and without inflamed meninges.
Aztreonam was administered as a single, 2-g intravenous dose to 25 patients with noninflamed meninges and to 9 patients with inflamed meninges. It was well tolerated and was detected in the cerebrospinal fluid at the initial sampling period at 1 h after the end of infusion. Aztreonam levels in the cerebrospinal fluid of patients with inflamed meninges were four times higher than those recorded for the same time period in patients with noninflamed meninges. Aztreonam concentrations in cerebrospinal fluid in the presence of normal and inflamed meninges exceeded the inhibitory and bactericidal concentrations for most gram-negative bacteria. Thus, a multiple-dose treatment regimen with 2-g intravenous doses every 6 h appears to be appropriate for clinical trials of aztreonam for the treatment of gram-negative bacillary meningitis which is caused by susceptible organisms.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000097:blood / Q000134:cerebrospinal fluid*; D001398:Aztreonam; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D005260:Female; D006801:Humans; D007700:Kinetics; D007958:Leukocyte Count; D008297:Male; D008578:Meninges / Q000473:pathology*; D008581:Meningitis / Q000134:cerebrospinal fluid* / Q000473:pathology; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D001398:Aztreonam